@Article{,
AUTHOR = {Gerald B. Brock},
TITLE = {Tadalafil: a new agent for erectile dysfunction},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {10},
YEAR = {2003},
NUMBER = {Suppl.1},
PAGES = {17--22},
URL = {http://www.techscience.com/CJU/v10nSuppl.1/63395},
ISSN = {1488-5581},
ABSTRACT = {Oral phosphodiesterase 5 (PDE5) inhibitors for the
treatment of erectile dysfunction are preferred by most
men, and are recommended in guidelines as first-line
therapy, because of convenience, high efficacy, and low
rates of side effects. Tadalafil (Cialis™) is a new agent
that has been studied in different patient populations. It
has a different molecular structure than other PDE5
inhibitors, and a different pharmacologic profile that
provides a longer period of effectiveness than other agents.
This article will review clinical trials on tadalafil, to provide
a comprehensive overview of its efficacy and safety.},
DOI = {}
}